(Q38485894)

3 September 2017

1 reference

title

Opportunities and challenges provided by crosstalk between signalling pathways in cancer (English)

1 reference

3 September 2017

2

1 reference

3 September 2017

A Prahallad

1

1 reference

3 September 2017

language of work or name

English

0 references

publication date

18 May 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

35

1 reference

3 September 2017

issue

9

1 reference

3 September 2017

page(s)

1073-1079

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Comprehensive molecular characterization of human colon and rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Reading between the lines; understanding drug response in the post genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Drug resistance to targeted therapies: déjà vu all over again

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Synthetic lethal approaches to breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Vemurafenib: the first drug approved for BRAF-mutant cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Improving outcomes in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

The tumour microenvironment as a target for chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Macrophage regulation of tumor responses to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Targeting the epigenome for treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Trials with 'epigenetic' drugs: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Romidepsin: a novel histone deacetylase inhibitor for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

ARID1B is a specific vulnerability in ARID1A-mutant cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Drug rechallenge and treatment beyond progression--implications for drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.151

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25982281

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2015.151

1 reference

Dimensions Publication ID

3 September 2017

1021485255

0 references

1 reference